Patents Assigned to Endo Pharmaceuticals, Inc.
-
Patent number: 11389443Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.Type: GrantFiled: October 16, 2017Date of Patent: July 19, 2022Assignee: ENDO PHARMACEUTICALS INC.Inventor: Harry Ahdieh
-
Patent number: 10406106Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: November 21, 2018Date of Patent: September 10, 2019Assignee: ENDO PHARMACEUTICALS INC.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 10251908Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: June 12, 2015Date of Patent: April 9, 2019Assignee: ENDO PHARMACEUTICALS INC.Inventors: Theodore H. Feller, Angela Sutterer, Thomas E. Fleming
-
Patent number: 10172798Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: July 24, 2017Date of Patent: January 8, 2019Assignee: Endo Pharmaceuticals Inc.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 10052344Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: October 8, 2015Date of Patent: August 21, 2018Assignee: ENDO PHARMACEUTICALS INC.Inventors: Theodore H. Feller, Angela Sutterer, Thomas E. Fleming
-
Patent number: 9926328Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt as a medicament and for the treatment and/or prevention of pain.Type: GrantFiled: September 12, 2016Date of Patent: March 27, 2018Assignee: ENDO PHARMACEUTICALS INC.Inventors: Andreas Fischer, Dagmar Peters-Groth, Dagmar Lischke
-
Patent number: 9820982Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphine which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: July 3, 2002Date of Patent: November 21, 2017Assignee: ENDO PHARMACEUTICALS INC.Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 9789103Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.Type: GrantFiled: July 21, 2014Date of Patent: October 17, 2017Assignee: ENDO PHARMACEUTICALS INC.Inventor: Harry Ahdieh
-
Publication number: 20160263035Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 23, 2016Publication date: September 15, 2016Applicant: Endo Pharmaceuticals Inc.Inventors: Anand R. BAICHWAL, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 9440986Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.Type: GrantFiled: February 4, 2015Date of Patent: September 13, 2016Assignee: ENDO PHARMACEUTICALS INC.Inventors: Andreas Fischer, Dagmar Peters-Groth, Dagmar Lischke
-
Patent number: 9351938Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: May 29, 2014Date of Patent: May 31, 2016Assignee: ENDO PHARMACEUTICALS INCInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 9278076Abstract: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.Type: GrantFiled: March 2, 2009Date of Patent: March 8, 2016Assignee: Endo Pharmaceuticals Inc.Inventors: Anand R. Baichwal, Paul Woodcock, Steve Labudzinski
-
Patent number: 9186330Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: June 30, 2014Date of Patent: November 17, 2015Assignee: Endo Pharmaceuticals INC.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
-
Patent number: 9050163Abstract: Provided herein is a two-part coupling assembly for re-connecting a first hollow body part to a second body part and an instrument and method for emplacement. The coupling assembly comprises coupling parts having securement elements that are actuated by separate deployment mechanisms of the instrument and attach to the first and second body parts. The first and second coupling parts having interconnecting elements that couple the two-part assembly together and re-connect the first and second body parts.Type: GrantFiled: March 20, 2012Date of Patent: June 9, 2015Assignee: Endo Pharmaceuticals Inc.Inventors: Roger P. Goldberg, Douglas S. Scherr, Anthony J. Wirtel, III, Rahul S. Nair, Nikhil R. Katre, Debasish Pradhan, Athar Solkar, Salman Kapadia, Arvind K. Gupta, Dinesh A. Diwakar, Rajesh T. Shelke, Jithin Ambujan
-
Publication number: 20140235652Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: ApplicationFiled: November 13, 2013Publication date: August 21, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
-
Patent number: 8808737Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.Type: GrantFiled: March 3, 2010Date of Patent: August 19, 2014Assignee: Endo Pharmaceuticals Inc.Inventor: Harry Ahdieh
-
Publication number: 20140221315Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.Type: ApplicationFiled: April 3, 2014Publication date: August 7, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
-
Publication number: 20140213552Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
-
Patent number: 8771732Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: August 24, 2006Date of Patent: July 8, 2014Assignee: Endo Pharmaceuticals IncInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
-
Patent number: 8765175Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: February 21, 2013Date of Patent: July 1, 2014Assignee: Endo Pharmaceuticals IncInventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au